Skip to main content
OpenTrials
Completed

NCT Number: NCT05011253

Electronic Triggers: Microhematuria Trigger

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hematuria Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hemorrhage Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Urination Disorders Urogenital Diseases Urologic Diseases

Age range

35 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NYU Langone

New York, 10016, United States

About this study

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 35 years of age or older
  • 3+ RBC on Urinalysis
  • Urinalysis sent during an outpatient encounter
  • any of the following: 60 years of age or older; RBC > 25; current or prior tobacco use; Gross Hematuria

Exclusion criteria

  • Under 35 years of age
  • Cystoscopy within 1 year prior to Urinalysis
  • Nitrite positive AND Leukocyte Esterase positive
  • Nitrite positive AND >100 WBC
  • Leukocyte Esterase positive AND >100 WBC
  • Know GU cancer diagnosis
  • Urinalysis ordered by urology provider

Treatment and study plan

Electronic Trigger Microhematuria Alert

Other

To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).

Primary outcomes

  1. Evaluation rate

    Time frame: 180 days of alert

    Urology evaluation with cystoscopy and appropriate imaging

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Official study title

Electronic Trigger for Microhematuria

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Aug 18, 2021
Registry last updated
Jul 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.